Business Wire

REPLY

23.3.2023 09:01:30 CET | Business Wire | Press release

Share
REPLY: "Everything can become a digital asset" Is the Paradigm Resulting From Reply's ‘Digital Assets Trends’ Research

The digital asset market is growing exponentially. Thanks to blockchain technology and the new generation of operators using tokenization platforms, it is possible to turn everything that can be digitally archived into a digital asset, with recognised value and established ownership. This is what emerges from Reply's new Digital Assets Trends’ research, based on the Reply SONAR platform. By analysing industry studies, scientific articles, patents, documents, and B2B content published in the last year, and integrating concrete experiences from Reply's clients, the study examines the main trends related to digital assets.

Tokenization is the first step to bringing real-world assets and financial instruments onto the blockchain, representing an opportunity especially for those of an illiquid nature (e.g., high-value art, public infrastructure, private equity). The main advantages of tokens include the construction of a peer-to-peer network without intermediaries that also serves as a decentralised network, end-to-end traceability with the possibility of proving ownership at any time, and automated record-keeping that simplifies every aspect of compliance.

"Digital assets still constitute less than 1% of the global financial system, but they have already grown exponentially and will continue this trend in the years to come," commented Filippo Rizzante, CTO of Reply. "Today, Reply is already supporting the demands of various financial institutions, as well as some major players in healthcare, energy, fashion, and public administration, in the adoption of digital assets enabled by a growing maturity of the regulatory framework and the intense work of central banks on their digital currencies."

The study essentially identifies 4 macro-categories of emerging digital assets, these are: payment tokens, non-fungible tokens (NFTs), utility tokens, and security tokens.

Payment tokens include cryptocurrencies and stablecoins. These currencies have not yet been issued by governments or other financial institutions, but are monitored and organised on a decentralised network. This network also serves as a secure ledger for each transaction, pending the first regulations that will come into force in 2024. The rapid and increased circulation of this type of asset has pushed central banks to explore their digital currencies, namely the Central Bank Digital Currencies, and the ECB has also started developing pilot projects for a digital Euro.

Non-fungible tokens are a digital representation of real assets or natively digital assets to be collected or used in virtual worlds. NFTs find application in various sectors, including asset management and the art market. Currently, they are not subject to any regulation and find the greatest potential within the metaverse.

Utility tokens allow the user to perform an action on a specific blockchain or decentralised application. They have been particularly popular for so-called initial coin offerings (ICOs), but today they are mainly used to redeem services and digital products in predefined ecosystems, such as those of cloud or online gaming.

Security tokens are a digital representation of a traditional financial instrument (stocks, bonds and derivatives). As digital assets, they offer additional benefits, including greater flexibility in the creation and distribution process for SMEs and startups. In addition to the existing security tokens that the European Investment Bank launched, the Reply SONAR platform has identified a growing interest in the tokenization of carbon credits, which concern a typically opaque and inefficient market like blockchain technology. This could revolutionise the monetary side of the life cycle of a tokenized carbon offset by tokenizing the credits.

The ‘Digital Assets Trends’ research can be downloaded here.

This study is part of the ‘Reply Trend SONAR’ series, which includes ‘Digital Experience Trends 2023’, ‘Metaverse: the potential beyond the hype’, and ‘Sustainability Trends’.

Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005053/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye